Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study CANCER Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Goekbuget, N., O'Brien, S. M., Jabbour, E., Wang, T., White, J., Sleight, B., Vandendries, E., Advani, A. S. 2019; 125 (14): 2474–87
View details for DOI 10.1002/cncr.32116
View details for Web of Science ID 000476763700018